Long-term Survival and Functional Outcomes of Critically Ill Patients with Hematologic Malignancies: a Canadian Multicenter Prospective Study
Overview
Authors
Affiliations
Purpose: Patients with hematologic malignancy (HM) commonly develop critical illness. Their long-term survival and functional outcomes have not been well described.
Methods: We conducted a prospective, observational study of HM patients admitted to seven Canadian intensive care units (ICUs) (2018-2020). We followed survivors at 7 days, 6 months and 12 months following ICU discharge. The primary outcome was 12-month survival. We evaluated functional outcomes at 6 and 12 months using the functional independent measure (FIM) and short form (SF)-36 as well as variables associated with 12-month survival.
Results: We enrolled 414 patients including 35% women. The median age was 61 (interquartile range, IQR: 52-69), median Sequential Organ Failure Assessment (SOFA) score was 9 (IQR: 6-12), and 22% had moderate-severe frailty (clinical frailty scale [CFS] ≥ 6). 51% had acute leukemia, 38% lymphoma/multiple myeloma, and 40% had received a hematopoietic stem cell transplant (HCT). The most common reasons for ICU admission were acute respiratory failure (50%) and sepsis (40%). Overall, 203 (49%) were alive 7 days post-ICU discharge (ICU survivors). Twelve-month survival of the entire cohort was 21% (43% across ICU survivors). The proportion of survivors with moderate-severe frailty was 42% (at 7 days), 14% (6 months), and 8% (12 months). Median FIM at 7 days was 80 (IQR: 50-109). Physical function, pain, social function, mental health, and emotional well-being were below age- and sex-matched population scores at 6 and 12 months. Frailty, allogeneic HCT, kidney injury, and cardiac complications during ICU were associated with lower 12- month survival.
Conclusions: 49% of all HM patients were alive at 7 days post-ICU discharge, and 21% at 12 months. Survival varied based upon hematologic diagnosis and frailty status. Survivors had important functional disability and impairment in emotional, physical, and general well-being.
Wang J, Zhang J, Zhang B, Cao Y, Guo Y, Yu P Zhonghua Xue Ye Xue Za Zhi. 2025; 46(1):31-38.
PMID: 40059679 PMC: 11886445. DOI: 10.3760/cma.j.cn121090-20241130-00510.
Clinical characteristics and prognostic factors of sepsis in patients with malignancy.
Hong G, Ju H, Oh D, Lee S, Park M, Lee H Sci Rep. 2025; 15(1):7078.
PMID: 40016348 DOI: 10.1038/s41598-025-87457-y.
Atallah F, Rosa R, Puxty K Crit Care Sci. 2024; 36:e20240262en.
PMID: 39699392 PMC: 11634240. DOI: 10.62675/2965-2774.20240262-en.
Munshi L, Dumas G, Mehta S Intensive Care Med. 2024; 50(11):1944.
PMID: 39352486 DOI: 10.1007/s00134-024-07614-1.
Bredin S, Decroocq J, Devautour C, Charpentier J, Vigneron C, Pene F Ann Intensive Care. 2024; 14(1):143.
PMID: 39259434 PMC: 11390996. DOI: 10.1186/s13613-024-01372-5.